Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - phenylephrine hydrochloride, quantity: 10 mg/ml - injection, solution - excipient ingredients: water for injections; sodium citrate dihydrate; sodium metabisulfite; nitrogen; sodium chloride; citric acid - indications as at 01 jan 1991 : phenylephrine hydrochloride is intended for the maintenance of an adequate level of blood pressure during spinal and inhalation anesthesia and for the treatment of vascular failure in shock, shock-like states, and drug-induced hypotension, of hypersensitivity. it is also employed to overcome paroxysmal supraventricular tachycardia, to prolong spinal anesthesia, and as a vasoconstrictor in regional analgesia.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - glipizide, quantity: 5 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; maize starch; lactose monohydrate; stearic acid - minidiab is indicated as an adjunct to diet and exercise for the control of hyperglycaemia and its associated symptomatology in patients with non-insulin-dependent diabetes mellitus (niddm; type ii), formerly known as maturity-onset diabetes, after an adequate trial of dietary therapy has proved unsatisfactory. in initiating treatment for non-insulin-dependent diabetes, diet should be emphasised as the primary form of treatment. caloric restriction and weight loss are essential in the obese diabetic patient. proper dietary management alone may be effective in controlling the blood glucose and symptoms of hyperglycaemia. the importance of regular physical activity should also be stressed, and cardiovascular risk factors should be identified and corrective measures taken where possible. if this treatment program fails to reduce symptoms and/or blood glucose the use of an oral sulphonylurea or insulin should be considered. use of minidiab must be viewed by both the physician and patient as a treatment in additio

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - noradrenaline (norepinephrine) acid tartrate monohydrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - colestipol hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - potassium chloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - potassium chloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - potassium chloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - doxepin hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - palbociclib, quantity: 100 mg - capsule, hard - excipient ingredients: magnesium stearate; iron oxide yellow; silicon dioxide; iron oxide red; microcrystalline cellulose; sodium starch glycollate type a; lactose monohydrate; titanium dioxide; gelatin; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; simethicone; ethanol; shellac; sulfuric acid - ibrance is indicated for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer in combination with: ? an aromatase inhibitor as initial endocrine-based therapy ? fulvestrant in patients who have received prior therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - palbociclib, quantity: 75 mg - capsule, hard - excipient ingredients: silicon dioxide; iron oxide yellow; iron oxide red; titanium dioxide; magnesium stearate; sodium starch glycollate type a; gelatin; lactose monohydrate; microcrystalline cellulose; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; simethicone; ethanol; shellac; sulfuric acid - ibrance is indicated for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer in combination with: ? an aromatase inhibitor as initial endocrine-based therapy ? fulvestrant in patients who have received prior therapy.